Travere Therapeutics (TVTX)
(Real Time Quote from BATS)
$9.59 USD
+0.87 (9.98%)
Updated Jul 9, 2024 03:54 PM ET
3-Hold of 5 3
F Value F Growth F Momentum F VGM
Price, Consensus and EPS Surprise
TVTX 9.59 +0.87(9.98%)
Will TVTX be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for TVTX based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for TVTX
Travere (TVTX) Stock Jumps 5.2%: Will It Continue to Soar?
Ligand (LGND) Beats Q1 Earnings, Misses Sales Estimates
TVTX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Here's What Key Metrics Tell Us About Travere (TVTX) Q1 Earnings
Travere Therapeutics (TVTX) Reports Q1 Loss, Misses Revenue Estimates
Analysts Estimate Arcturus Therapeutics (ARCT) to Report a Decline in Earnings: What to Look Out for
Other News for TVTX
Travere Therapeutics to Present at the H.C. Wainwright 3rd Annual Kidney Virtual Conference
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Analysts Are Bullish on Top Healthcare Stocks: Mineralys Therapeutics, Inc. (MLYS), Teladoc (TDOC)
Analysts Offer Insights on Healthcare Companies: Travere Therapeutics (TVTX), Fortrea Holdings Inc. (FTRE) and Cellectis SA (CLLS)
Travere gains on Novartis data for Filspari rival, Calliditas buyout